Avoro Capital Advisors | Activity | F4Avoro Capital Advisors Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Team Change
Susana Wilson Hawken joined Avoro as an Associate, moving from Norwest Venture Partners.
Susana Wilson Hawken joined as Associate
Added recently
Added Uya Chuluunbaatar as a Partner at Avoro Ventures.
Uya Chuluunbaatar joined Avoro Ventures as Partner
New Fund
Announced the final close of Avoro Ventures' inaugural fund.
Avoro Ventures Fund I final close
Added recently
Investment
Participated in Hemab Therapeutics' $135M Series B financing to advance prophylactic treatments for bleeding and thrombotic disorders.
Hemab Therapeutics
Added recently
Investment
Backed Ethyreal Bio's $101M emergence-from-stealth financing to advance ETHY-001, an anti-TSHR antibody for thyroid eye disease and Graves' disease.
Ethyreal Bio
Exit
Portfolio company ViceBio was acquired by Sanofi for US$1.6 billion.
Vicebio
Investment
Participated in Ottimo Pharma's over-$140M Series A financing.
Ottimo Pharma
Investment
Participated in ViceBio's $100M Series B financing alongside initiation of a Phase 1 RSV/hMPV bivalent vaccine study.
Vicebio
Team Change
Added Mark Chin as a Partner at Avoro Ventures.
Mark Chin joined Avoro Ventures as Partner